[go: up one dir, main page]

MA43288B1 - Procédés de production et formes cristallines d'un inhibiteur mdm2 - Google Patents

Procédés de production et formes cristallines d'un inhibiteur mdm2

Info

Publication number
MA43288B1
MA43288B1 MA43288A MA43288A MA43288B1 MA 43288 B1 MA43288 B1 MA 43288B1 MA 43288 A MA43288 A MA 43288A MA 43288 A MA43288 A MA 43288A MA 43288 B1 MA43288 B1 MA 43288B1
Authority
MA
Morocco
Prior art keywords
production processes
crystal forms
mdm2 inhibitor
intermediates
chlorophenyl
Prior art date
Application number
MA43288A
Other languages
English (en)
Other versions
MA43288A1 (fr
Inventor
Matthew Bio
Sebastien Caille
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA43288(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA43288A1 publication Critical patent/MA43288A1/fr
Publication of MA43288B1 publication Critical patent/MA43288B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)

Abstract

La présente invention concerne des procédés de production d'acide 2-((3r,5r,6s)-5-(3- chlorophényl)-6-(4-chlorophényl)-l-((s)-l-(isopropylsulfonyl)-3-méthylbutan-2-yl)-3- méthyl-2-oxopipéridin-3-yl)acétique ainsi que des intermédiaires et des procédés de production des intermédiaires. L'invention concerne également des formes cristallines du composé et les intermédiaires.
MA43288A 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2 MA43288B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10

Publications (2)

Publication Number Publication Date
MA43288A1 MA43288A1 (fr) 2020-04-30
MA43288B1 true MA43288B1 (fr) 2020-10-28

Family

ID=51063849

Family Applications (3)

Application Number Title Priority Date Filing Date
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA43288A MA43288B1 (fr) 2013-06-10 2015-12-23 Procédés de production et formes cristallines d'un inhibiteur mdm2

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MA38714A MA38714A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2
MA53572A MA53572A1 (fr) 2013-06-10 2014-06-09 Procédés de production et formes cristallines d'un inhibiteur mdm2

Country Status (38)

Country Link
US (10) US9376386B2 (fr)
EP (2) EP3805232A1 (fr)
JP (4) JP6998655B2 (fr)
KR (4) KR20160018576A (fr)
CN (3) CN105358530A (fr)
AP (1) AP2015008891A0 (fr)
AR (2) AR096582A1 (fr)
AU (5) AU2014278428B2 (fr)
BR (2) BR122020003153B1 (fr)
CA (4) CA3201958A1 (fr)
CL (3) CL2015003589A1 (fr)
CR (2) CR20210290A (fr)
CY (1) CY1123661T1 (fr)
DK (1) DK3008039T3 (fr)
EA (3) EA031254B1 (fr)
ES (1) ES2851023T3 (fr)
HR (1) HRP20202065T1 (fr)
HU (1) HUE053047T2 (fr)
IL (4) IL297860A (fr)
JO (2) JOP20200296A1 (fr)
LT (1) LT3008039T (fr)
MA (3) MA38714A1 (fr)
MX (2) MX379872B (fr)
MY (2) MY205257A (fr)
NZ (1) NZ714821A (fr)
PE (2) PE20210153A1 (fr)
PH (2) PH12020550916A1 (fr)
PL (1) PL3008039T3 (fr)
PT (1) PT3008039T (fr)
RS (1) RS61192B1 (fr)
SG (2) SG10201801402XA (fr)
SI (1) SI3008039T1 (fr)
SM (1) SMT202100013T1 (fr)
TN (1) TN2015000521A1 (fr)
TW (3) TWI698428B (fr)
UA (1) UA121301C2 (fr)
UY (1) UY35605A (fr)
WO (1) WO2014200937A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
CA2906538C (fr) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Composes morpholinone d'acide heteroaryle utilises comme inhibiteurs de mdm2 pour le traitement du cancer
JOP20200296A1 (ar) * 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
JP2021523220A (ja) * 2018-04-30 2021-09-02 カルトス セラピューティクス，インコーポレイテッド がんの治療方法
US20220054472A1 (en) * 2018-05-25 2022-02-24 Kartos Therapeutics, Inc. Methods of Treating Myeloproliferative Neoplasms
EP3843733A4 (fr) * 2018-08-31 2022-08-24 Amgen Inc. Procédés de préparation d'un inhibiteur de mdm2
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
CN116194088A (zh) 2020-08-27 2023-05-30 大冢制药株式会社 使用mdm2拮抗剂治疗癌症的生物标志物
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
EP4382509A1 (fr) * 2021-08-05 2024-06-12 Bio-Pharm Solutions Co., Ltd. Forme cristalline de phénylcarbamate et son procédé de préparation
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
WO2023039161A1 (fr) * 2021-09-09 2023-03-16 Kartos Therapeutics Procédés de traitement du cancer dépendant de l'expression du gène myc
WO2023056069A1 (fr) 2021-09-30 2023-04-06 Angiex, Inc. Conjugués agent de dégradation-anticorps et leurs procédés d'utilisation
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2024240858A1 (fr) 2023-05-23 2024-11-28 Valerio Therapeutics Molécules protac dirigées contre un système de réparation de dommages à l'adn et leurs utilisations

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
CH436295A (de) 1961-11-13 1967-05-31 Mcneilab Inc Verfahren zur Herstellung neuer 3-Morpholinone
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (fr) 1991-03-07 1995-08-31 Fisons Corporation Derives de diphenyl-2-piperidinone et -2-pyrrolidinone possedant une activite anticonvulsivante et neuroprotectrice
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
EP1186603A3 (fr) 1994-08-19 2003-07-09 Abbott Laboratories Procédés de préparation d'antagonistes de l'endotheline
EP0885215B1 (fr) 1996-02-13 2006-04-19 Abbott Laboratories Derives de pyrrolidine a substitution benzo-1,3-dioxolyl et benzofuranyl servant d'antagonistes de l'endotheline
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
CA2297894A1 (fr) 1997-08-04 1999-02-11 Abbott Laboratories Antagonistes d'endotheline
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (fr) 2000-08-31 2002-03-07 Abbott Laboratories Antagonistes de l'endotheline
WO2002042731A2 (fr) * 2000-11-20 2002-05-30 Parallel Synthesis Technologies, Inc. Procedes et dispositifs pour une cristallisation a haut debit
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE60229059D1 (de) 2001-05-08 2008-11-06 Univ Yale Proteomimetische verbindungen und verfahren
EP1395560A1 (fr) 2001-05-23 2004-03-10 Ucb, S.A. Derives d'acide alcanoique 2-oxo-piperidinyl- et 2-oxo-azepanyle destines au traitement de l'epilepsie et d'autres troubles neurologiques
RU2305095C2 (ru) 2001-12-18 2007-08-27 Ф.Хоффманн-Ля Рош Аг Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
KR100832277B1 (ko) 2004-05-18 2008-05-26 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP2007297283A (ja) * 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
BRPI0516609A (pt) 2004-10-18 2008-04-29 Amgen Inc composto ou sal, hidrato, ou estereoisÈmero farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, uso de um composto
BRPI0607863B8 (pt) 2005-02-18 2021-05-25 Mitsubishi Pharma Corp sal cristalino 2,5-bromidrato de 3-{(2s,4s)-4-[4-(3-metil-1-fenil-1h-pirazol-5-il)piperazin-1-il]pirrolidin-2-ilcarbonil}tiazolidina e seu processo de preparo
KR101139263B1 (ko) 2005-03-16 2012-05-16 에프. 호프만-라 로슈 아게 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의그의 용도
DK1871368T3 (da) 2005-04-04 2011-09-19 Eisai R&D Man Co Ltd Dihydropyridinforbindelser til neurodegenerative sygdomme og demens
CA2610838A1 (fr) * 2005-06-07 2006-12-14 Ramot At Tel Aviv University Ltd. Nouveaux sels de medicaments psychotropes conjugues et leurs procedes de preparation
US7893268B2 (en) * 2005-07-27 2011-02-22 University Of Toledo Epithiolone analogues
BRPI0619236A2 (pt) 2005-12-01 2011-09-20 Hoffmann La Roche derivados de 2,4,5-trifenil imidazolina, composição farmacêutica que os compreende, uso e processo para a sìntese dos mesmos
JP5199885B2 (ja) 2006-01-18 2013-05-15 アムジエン・インコーポレーテツド プロテインキナーゼｂ（ｐｋｂ）阻害剤としてのチアゾール化合物
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
CN101595107A (zh) 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
US7888375B2 (en) 2006-07-19 2011-02-15 The University Of Georgia Research Foundation, Inc Pyridinone diketo acids: inhibitors of HIV replication
WO2008021339A2 (fr) 2006-08-15 2008-02-21 Wyeth Pyrrolidine et dérivés associés utiles en tant que modulateurs des récepteurs de la progestérone
WO2008021338A2 (fr) 2006-08-15 2008-02-21 Wyeth Dérivés d'oxazolidone tricycliques utiles en tant que modulateurs du récepteur de la progestérone
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CA2681136C (fr) 2007-03-23 2012-05-22 Amgen Inc. Composes heterocycliques et leurs utilisations
AU2008231384B2 (en) 2007-03-23 2011-09-15 Amgen Inc. Heterocyclic compounds and their use
DK2139882T3 (en) 2007-03-23 2014-03-10 Amgen Inc 3-substituted quinoline or quinoxaline derivatives and their use as inhibitors of phosphatidylinositol 3-kinase (PI3K)
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (fr) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Antagonistes p53/mdm2/mdm4 sélectifs et à action double
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (fr) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones et composés hétérocycliques apparentés comme potentialisateurs de récepteurs du glutamate
ES2385692T3 (es) 2007-07-09 2012-07-30 Astrazeneca Ab Derivados de morfolino pirimidina usados en enfermedades relacionadas con mTOR quinasa y/o PI3K
CA2692713A1 (fr) 2007-07-17 2009-01-22 Amgen Inc. Modulateurs heterocycliques de pkb
AU2008276512A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
AU2008282728B2 (en) 2007-08-02 2012-04-19 Amgen Inc. Pl3 kinase modulators and methods of use
EP2203437B1 (fr) 2007-10-09 2012-11-07 F. Hoffmann-La Roche AG Cis-imidazolines chirales
WO2009085230A1 (fr) 2007-12-19 2009-07-09 Amgen Inc. Inhibiteurs de la pi3 kinase
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
WO2009082038A2 (fr) 2007-12-26 2009-07-02 Eisai R & D Management Co., Ltd. Antagonistes des récepteurs ampa et zonisamide pour le traitement de l'épilepsie
CA2718959A1 (fr) 2008-03-21 2009-09-24 Chlorion Pharma, Inc. Composes de pyrrolidine et de piperidine substitues, leurs derives et procedes de traitement de la douleur
WO2009155121A2 (fr) 2008-05-30 2009-12-23 Amgen Inc. Inhibiteurs de la pi3 kinase
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
WO2010030704A2 (fr) * 2008-09-10 2010-03-18 Achaogen, Inc. Analogues d’aminoglycosides antibactériens
TW201011009A (en) 2008-09-15 2010-03-16 Priaxon Ag Novel pyrrolidin-2-ones
PE20110367A1 (es) 2008-09-18 2011-06-13 Hoffmann La Roche DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
WO2010083246A1 (fr) 2009-01-15 2010-07-22 Amgen Inc. Thiazoles substitués par fluoroisoquinoléine et leurs méthodes d'application
AU2010216239B2 (en) 2009-02-18 2012-06-14 Amgen Inc. Indole/benzimidazole compounds as mTOR kinase inhibitors
WO2010108074A2 (fr) 2009-03-20 2010-09-23 Amgen Inc. Inhibiteurs de pi3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
MX2011012037A (es) 2009-05-13 2012-02-28 Amgen Inc Compuestos de heteroarilo como inhibidores de pikk.
US8754089B2 (en) 2009-06-25 2014-06-17 Amgen Inc. Heterocyclic compounds and their uses
EP2445900B1 (fr) 2009-06-25 2016-03-02 Amgen, Inc Derives polycycliques de pyridine et leur utilisation dans le traitement de (entre autres) arthrite rhumatoïde et de troubles similaires
JP2012531438A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびその使用
JP2012531436A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 複素環式化合物およびそれらのｐｉ３ｋ活性阻害剤としての使用
BR112012008075A2 (pt) 2009-08-26 2016-03-01 Novartis Ag compostos de heteroarila tetrassubstituídos e seu uso como moduladores de mdm2 e/ou mdm4
JP2013507391A (ja) * 2009-10-09 2013-03-04 アカオジェン インコーポレイテッド 抗ウイルスアミノグリコシド類似体
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CN103843105A (zh) * 2010-02-10 2014-06-04 摩奇有限公司(d/b/aVoxa) 暗视野像差矫正电子显微镜
IT1399923B1 (it) * 2010-05-11 2013-05-09 Cbb Net S A Procedimento di preparazione di sali dell'acido (r) alfa-lipoico loro formulazione ed uso nelle composizioni farmaceutiche in forma di compresse che li contengono
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
EP3581574A1 (fr) * 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. Composition pour administration orale à utiliser dans le traitement du cancer, d'une maladie inflammatoire ou d'une maladie auto-immune
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
KR101921102B1 (ko) * 2011-04-28 2018-11-22 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 아조디카본아미드의 신규 제조법
TW201309651A (zh) * 2011-06-29 2013-03-01 Otsuka Pharma Co Ltd 阿立哌唑（ａｒｉｐｉｐｒａｚｏｌｅ）無水物Ｂ形結晶微粒子之製造方法
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
WO2014130470A1 (fr) 2013-02-19 2014-08-28 Amgen Inc. Cis-morpholinone et autres composés servant d'inhibiteurs de mdm2 pour le traitement du cancer
JP6266659B2 (ja) 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤
CA2906538C (fr) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Composes morpholinone d'acide heteroaryle utilises comme inhibiteurs de mdm2 pour le traitement du cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط

Also Published As

Publication number Publication date
EA201592305A1 (ru) 2016-05-31
BR112015031004A2 (pt) 2020-05-12
US20220280496A1 (en) 2022-09-08
KR20240159641A (ko) 2024-11-05
TWI698428B (zh) 2020-07-11
AU2018260844A1 (en) 2018-11-22
IL281807B2 (en) 2023-04-01
CN110003092A (zh) 2019-07-12
US20160287570A1 (en) 2016-10-06
US9376386B2 (en) 2016-06-28
HRP20202065T1 (hr) 2021-02-19
MX2015016856A (es) 2016-04-07
CA3200532A1 (fr) 2014-12-18
TN2015000521A1 (en) 2017-04-06
MX2019012007A (es) 2019-11-11
SMT202100013T1 (it) 2021-03-15
IL242622B (en) 2019-06-30
JP7263439B2 (ja) 2023-04-24
MY205257A (en) 2024-10-09
SG11201509896VA (en) 2016-01-28
IL297860A (en) 2023-01-01
LT3008039T (lt) 2021-01-25
WO2014200937A1 (fr) 2014-12-18
EA202091612A1 (ru) 2020-10-05
ES2851023T3 (es) 2021-09-02
CY1123661T1 (el) 2022-03-24
CR20160010A (es) 2016-02-04
IL242622A0 (en) 2016-02-01
MA53572A1 (fr) 2021-10-29
AR096582A1 (es) 2016-01-20
PE20210153A1 (es) 2021-01-26
AU2022271425B2 (en) 2024-06-13
AR119727A2 (es) 2022-01-05
SG10201801402XA (en) 2018-04-27
US20160289178A1 (en) 2016-10-06
EP3008039B1 (fr) 2020-11-11
CA2914723C (fr) 2021-06-15
CL2021000566A1 (es) 2021-09-03
CL2015003589A1 (es) 2016-06-17
US20160289243A1 (en) 2016-10-06
UY35605A (es) 2015-01-30
CA3201958A1 (fr) 2014-12-18
US9757367B2 (en) 2017-09-12
PT3008039T (pt) 2021-01-13
JP2020147573A (ja) 2020-09-17
PL3008039T3 (pl) 2021-04-19
JP6998655B2 (ja) 2022-02-04
NZ753956A (en) 2020-12-18
PH12015502705B1 (en) 2022-04-27
CA3115609A1 (fr) 2014-12-18
IL281807A (en) 2021-05-31
JP2016528179A (ja) 2016-09-15
TW201922705A (zh) 2019-06-16
JP2021130685A (ja) 2021-09-09
KR20230019216A (ko) 2023-02-07
JO3768B1 (ar) 2021-01-31
TWI791153B (zh) 2023-02-01
US20140364455A1 (en) 2014-12-11
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
AU2020267169A1 (en) 2020-12-03
AU2022271425A1 (en) 2022-12-22
US9801867B2 (en) 2017-10-31
PH12020550916A1 (en) 2024-03-25
BR112015031004B1 (pt) 2022-09-20
US9623018B2 (en) 2017-04-18
US20230301974A1 (en) 2023-09-28
UA121301C2 (uk) 2020-05-12
CL2019000056A1 (es) 2019-05-03
JOP20200296A1 (ar) 2017-06-16
JP6891322B2 (ja) 2021-06-18
CA3115609C (fr) 2023-08-08
TWI649306B (zh) 2019-02-01
MA43288A1 (fr) 2020-04-30
AU2020267169B2 (en) 2022-08-25
MX379872B (es) 2025-03-11
CN105358530A (zh) 2016-02-24
AP2015008891A0 (en) 2015-11-30
US20160289190A1 (en) 2016-10-06
CA2914723A1 (fr) 2014-12-18
HUE053047T2 (hu) 2021-06-28
IL266504B (en) 2021-04-29
IL281807B (en) 2022-12-01
JP2023089126A (ja) 2023-06-27
CR20210290A (es) 2021-07-23
DK3008039T3 (da) 2021-01-04
US9855259B2 (en) 2018-01-02
US20200281912A1 (en) 2020-09-10
US20160264526A1 (en) 2016-09-15
AU2018260844B2 (en) 2020-08-13
NZ714821A (en) 2020-10-30
IL266504A (en) 2019-07-31
EA201891642A1 (ru) 2019-08-30
MY194848A (en) 2022-12-19
SI3008039T1 (sl) 2021-03-31
CN110627708A (zh) 2019-12-31
KR20210121270A (ko) 2021-10-07
EA031254B1 (ru) 2018-12-28
PE20160113A1 (es) 2016-03-03
AU2024216533A1 (en) 2024-09-19
PH12015502705A1 (en) 2016-03-14
AU2014278428B2 (en) 2018-11-15
EP3805232A1 (fr) 2021-04-14
AU2014278428A1 (en) 2015-11-26
US20180092898A1 (en) 2018-04-05
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
EP3008039A1 (fr) 2016-04-20
TW202035370A (zh) 2020-10-01
BR122020003153B1 (pt) 2022-09-27

Similar Documents

Publication Publication Date Title
MA43288B1 (fr) Procédés de production et formes cristallines d'un inhibiteur mdm2
RS54030B1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2014028597A3 (fr) Composés indazole et indole à substitution cyclohexyl et 3-cyclohexenyl
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
MA41607B1 (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
MY199269A (en) Compositions and methods of use of phorbol esters
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
EA201071367A1 (ru) Соли соединений ингибиторов вич
EA201390336A1 (ru) Способ получения промежуточного соединения для синтеза лекарственного средства
DK1926732T3 (da) Fremgangsmåde til fremstillingen af carbapenemforbindelser
EA201170736A1 (ru) Синтез и новые солевые формы (r)-3-((e)-2-(пирролидин-3-ил)винил)-5-(тетрагидропиран-4-илокси) пиридина
EA201170481A1 (ru) Сокристаллы
IN2013MU00916A (fr)
ATE509945T1 (de) Chirale mit phosphonsäureester- oder phosphonsäure- substituierte verbindungen
EA202190632A1 (ru) Способы получения ингибитора mdm2
WO2010129848A3 (fr) 2,6-dioxo-1, 2, 3, 6-tétrahydropyrimidine-4-carboxamides
MX2016002763A (es) Formas cristalinas de un derivado de pirrolidona util en el tratamiento de la enfermedad de alzheimer y preparacion de las mismas.
MX2014002343A (es) Inhibidores de parp.